Back

Dapagliflozin versus empagliflozin and major adverse cardiovascular events in type 2 diabetes: a nationwide cohort study

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Diabetes, obesity, and the heart Antidiabetic Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Amna Alhakak

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)

6 More presentations in this session

Presentation thumbnail
GLP1-RA versus DPP4 inhibitors on cardiovascular outcomes: A three-year real-world analysis
Doctor K. Soerensen (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
The role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in epicardial adipose tissue modulation: a meta-analysis
Doctor P. Theofilis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
The effect of Glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in type 2 diabetes mellitus patients with coronary artery disease
Doctor J. Tjerkaski (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Impact of SGLT2 inhibitor dapagliflozin on myocardial protein profile in rats with long-standing Type 1 diabetes mellitus
Doctor E. Rodrigues (Botucatu, BR)
Abstract Slides Video
Presentation thumbnail
Body mass index and clinical outcomes in patients with diabetes and stable coronary artery disease in THEMIS
Doctor M. Pareek (Copenhagen, DK)
Abstract Slides Video

Access the full session

Session thumbnail
Diabetes, obesity, and the heart

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Comparison of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in myocardial infarction patients with type 2 diabetes
thumbnail
Congress Presentation
GLP1-RA versus DPP4 inhibitors on cardiovascular outcomes: A three-year real-world analysis
thumbnail
Congress Presentation
Sodium-Glucose Co-Transporter 2 inhibitors and cardiovascular outcomes: a trial-similar population vs. a broad population

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources